Killoran et al. (2023) [72] reported a study on novel CGRP receptor antagonists for migraine therapy that involved improving the antagonist potency of the known peptide (34Pro,35Phe)CGRP27–37 through the structural modification of truncated C-terminal CGRP peptides. The gene discussed is CALCA; the disease is migraine disorder.